Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp; Jacek Szepietowski; Leon  Kircik; Darryl Toth; Lawrence Eichenfeld; Seth Forman; Michael Kuligowski; May Venturanza; Kang Sun; Eric Simpson

doi:10.25251/skin.5.supp.63

Kim Papp

Probity Medical Research, Waterloo, ON, Canada

Jacek Szepietowski

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland

Leon Kircik

Mount Sinai

Darryl Toth

XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

Lawrence Eichenfeld

UC San Diego

Seth Forman

ForCare Clinical Research, Tampa, FL, USA;

Michael Kuligowski

Incyte Corporation, Wilmington, DE, USA

May Venturanza

Incyte Corporation, Wilmington, DE, USA

Kang Sun

Incyte Corporation, Wilmington, DE, USA

Eric Simpson

Oregon Health & Science University, Portland, OR, USA

Keywords

safety, ruxolitinib cream, atopic dermatitis

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Bao L, et al. JAKSTAT.2013;2(3):e24137.

3. Oetjen LK, et al. Cell. 2017;171(1): 217-228.

4. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.63

How to Cite

Papp, K., Szepietowski, J., Kircik, L. ., Toth, D., Eichenfeld, L., Forman, S., Kuligowski, M., Venturanza, M., Sun, K., & Simpson, E. (2021). Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine, 5(6), s63. https://doi.org/10.25251/skin.5.supp.63

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Joseph Raoof, Deirdre Hooper, Angela Moore, Martin Zaiac, Tory Sullivan, Leon Kircik, Edward Lain, Jasmina Jankivevic, Iain Stuart, FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Linda Stein Gold, MD, Leon H. Kircik, MD, Emil A Tanghetti, MD, Hilary Baldwin, MD, Zoe D. Draelos, MD, Michael Gold, MD, Edward Lain, MD, MBA, David M Pariser, MD, Neil Sadick, MD, Radhakrishnan Pillai, PhD, Varsha Bhatt, PhD, Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Neil Sadick, Fran Cook-Bolden, Kenneth Beer, Zoe Draelos, Leon Kircik, Emil Tanghetti, Eric Guenin, Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Different Adult Age Groups , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Leon Kircik, Lawrence Green, Joshua Zeichner, Javier Alonso-Llamazares, Abby Jacobson, Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Hilary Baldwin, Emmy Graber, Richard G Fried, Evan A Rieder, Julie C Harper, Andrew F Alexis, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
James Del Rosso, Leon Kircik, Cheryl Effron, Zoe Draelos, Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study Evaluating Efficacy and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Joseph Merola, Lawrence Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Petra Staubach, Sue Cheng, Shauna Jardon, Maria Paris, Mindy Chen, Kim Papp, Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Linda Stein Gold, Kim Papp, Charles Lynde, Edward Lain, Melinda Gooderham, Sandra Johnson, Nabil Kerrouche, Gregor Schafer, Concurrent Administration of Ivermectin 1% Cream with Brimonidine 0.33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate-to-Severe Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Andrew Blauvelt, Lawrence Eichenfeld, Michael Kuligowski, May Venturanza, Kang Sun, Jonathan Silverberg, Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

<< < 3 4 5 6 7 8 9 10 11 12 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)